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Background: In preclinical models, the proteasome inhibitor bort-
ezomib (PS-341) inhibits the growth of small cell lung cancer
(SCLC) by inhibiting the antiapoptotic Bcl-2 signaling pathway. We
conducted a phase II trial of PS-341 in previously treated patients
with platinum-sensitive and -refractory extensive stage SCLC to
determine response rate, toxicity, and survival.
Methods: Patients with histologically confirmed SCLC, measurable
disease, Zubrod performance status 0–1, and previous treatment
with platinum-based therapy were enrolled. They were stratified by
platinum-sensitivity status: sensitive (relapse 90 days after plati-
num) or refractory (progression during or 90 days after platinum).
PS-341 was administered at 1.3 mg/m2 intravenously on days 1, 4,
8, and 11 every 21 days.
Results: Of 56 eligible patients, 28 were platinum sensitive and 28
refractory. Twenty-nine patients (52%) had received two or more
previous chemotherapy regimens. One platinum-refractory patient
had a confirmed partial response. A majority of assessable patients
(91%) progressed. Median progression-free survival and overall
survival were 1 month and 3 months, respectively. Ten patients
(18%) discontinued treatment due to adverse events or side effects.
Conclusion: Although PS-341 induced a response in a patient with
platinum-refractory disease, it has limited single-agent activity in
this heavily pretreated cohort. As shown in preclinical models,
testing of PS-341 in combination with an apoptotic trigger such as
chemotherapy, is a rational clinical approach. A trial of topotecan
plus PS-341 has been initiated to test this concept.
Key Words: Small cell lung cancer, Proteasome inhibition, Bort-
ezomib, Bcl-2.
(J Thorac Oncol. 2006;1: 996–1001)
Lung cancer will be diagnosed in approximately 180,000Americans in 2006. Of these patients, approximately 15%
will be diagnosed with small cell lung cancer (SCLC), a
virulent, aggressive malignancy that is usually disseminated
(or extensive) in 60% to 70% of patients at initial presenta-
tion.1 Patients with extensive stage SCLC are typically
treated with platinum-based chemotherapy regimens resulting
in high response rates and translating into improved survival
compared to single-agent chemotherapy. However, despite
the initial chemosensitivity of treatment-naive disease, nearly
all patients subsequently experience a recurrence and develop
chemoresistance.
Results of salvage chemotherapy for progressive or
relapsed disease are poor, with infrequent objective responses
and a median survival following disease progression of only
2 to 3 months.2 The activity of new chemotherapeutic agents
in previously treated SCLC can be distinguished based on the
response status to prior platinum-based chemotherapy. Three
categories of patients have been described: sensitive, resis-
tant, and refractory.3–5 Sensitive refers to patients who had a
first-line response that lasted 90 days after treatment was
completed. Refractory refers to patients who never responded
to first-line therapy or those whose cancer progressed during
first-line therapy. Resistant refers to patients who responded
initially, but experienced a recurrence within 90 days of
completion of their primary therapy. Resistant patients are
generally grouped together with refractory patients because
of their uniformly poor outcomes. The role of further therapy
for refractory and/or resistant patients remains a source of
controversy as these patients are thought to benefit less from
second-line chemotherapy. Alternatively, they are a poten-
tially unique group of patients to target when studying novel
agents with different mechanisms of action. For example,
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although the response rate to the topoisomerase I inhibitor
topotecan was approximately 38% in patients defined as plati-
num sensitive, almost no responses are observed in platinum-
refractory SCLC.6 This finding is also true for other new agents
evaluated in this clinical setting. Thus, novel agents with poten-
tial activity in recurrent or refractory SCLC ought to be evalu-
ated in the context of platinum-sensitivity status.
The conjugation of target proteins to ubiquitin followed
by proteasome degradation is an integral component of di-
verse cellular processes ranging from cell-cycle regulation to
signal transduction.7 The ubiquitin-proteasome pathway
plays a central role in the regulated degradation of intracel-
lular eukaryotic proteins that participate in cell cycle control
and tumor growth. The 26S proteasome is an adenosine
triphosphate–dependent multicatalytic protease that is central
to this degradative pathway. Among the many targets of the
26S proteasome are elements of the apoptotic pathway, spe-
cifically inhibitory B (IB).8–11 This protein regulates the
Bcl-BAX family of proteins by inhibiting nuclear factor B
(NF-B). In its activated state, NF-B promotes tumor cell
survival and resistance to therapy in many cell types, includ-
ing lung cancer, through induction of the antiapoptotic onco-
genes and survival factors such as Bcl-2 and Bcl-xL.12 Thus,
proteasome-mediated degradation of IB will result in
NF-B activation and, ultimately, resistance to apoptosis.
Bcl-2 is reported to be overexpressed in up to 90% of
SCLC tumors,13 whereas increased Bcl-2 expression has been
associated with chemotherapy resistance in SCLC by inhib-
iting apoptosis.14–18 In addition, expression of Bcl-2 is higher
in metastatic tumors compared to localized disease. Bort-
ezomib (PS-341) is a dipeptidyl boronic acid that is a specific
and selective inhibitor of the 26S proteasome. In light of high
Bcl-2 expression in SCLC and the potential role of protea-
some inhibition in regulating this pathway by increasing
tumor cell apoptosis, we conducted a phase II trial of bort-
ezomib in relapsed/refractory SCLC (SWOG 0327).
PATIENTS AND METHODS
The objectives of the study were to evaluate the effi-
cacy of PS-341 in previously treated platinum-sensitive and
platinum-refractory patients with extensive stage SCLC in
terms of response rate, to assess the qualitative and quanti-
tative toxicities of bortezomib in this patient cohort, and to
assess overall survival. All participating centers were re-
quired to have institutional review board approval for the
study and all patients provided informed consent.
Eligibility Criteria
To be eligible, patients had histologically or cytologi-
cally confirmed diagnosis of SCLC, measurable disease (by
plain radiographs, computed tomography scan, or magnetic
resonance imaging scan), Zubrod performance status 0–1,
and adequate end-organ function characterized by an absolute
granulocyte count 1500/l, a platelet count 100,000/l,
and acceptable hepatic and renal function. All patients must
have been previously treated with a platinum-based regimen.
There was no limit to the number of previous chemotherapy
regimens allowed. Patients must not have previously received
PS-341. A patient with known brain and/or leptomeningeal
metastases could be included only if asymptomatic on neu-
rologic examination and was not receiving corticosteroid
therapy to control symptoms. Patients with symptomatic
sensory neuropathy of grade 1 or higher were excluded
because of the potential for enhanced toxicity with PS-341.
Pregnant or nursing women were not eligible because of the
unknown risk of fetal harm from PS-341 therapy. Women/
men of reproductive potential who entered the study agreed to
use an effective contraceptive method. All patients gave
written informed consent to participate in this study in accor-
dance with institutional and federal guidelines.
Treatment
Treatment consisted of PS-341 as an intravenous bolus
on days 1, 4, 8, and 11 at a dose of 1.3 mg/m2 for each cycle.
Cycle length was 21 days. This study used the National
Cancer Institute Common Toxicity Criteria (CTC) Version
2.0 for toxicity and adverse event reporting. Interruptions and
delays of PS-341 therapy were allowed for up to 3 weeks for
grade 3 and 4 toxicities such as myelosuppression or neurop-
athy. A dose reduction to 1.0 mg/m2 was allowed for subse-
quent cycles if such toxicity were seen. If treatment delay
exceeded 3 weeks, the patient was removed from protocol
treatment.
Statistical Considerations
The primary endpoint was response rate. Secondary
endpoints included time to progression and overall survival.
Patients were stratified into platinum-sensitive or platinum-
refractory groups. Platinum-sensitive disease was defined as
an initial response to platinum-based chemotherapy and pro-
gression 90 days after the last platinum treatment, whereas
platinum-refractory disease was defined as no response to
platinum-based chemotherapy or progression during or 90
days after the last platinum treatment. In either stratum, a
response rate of 5% was considered inadequate to warrant
further evaluation of single-agent bortezomib at this schedule
and dose. A response rate of 20% was considered promis-
ing and further study would be recommended. Parallel patient
enrollment was implemented for both strata, and a two-stage
design proceeded separately for each stratum. Initially, 20
patients were to be accrued to each stratum. If no responses
were observed in the first 20 patients, then accrual was
stopped in that stratum with the conclusion that PS-341 was
not promising. If one or more responses were observed in the
first 20, an additional 20 patients were to be accrued to the
stratum. Five or more responses out of the total 40 patients in
a stratum were considered as evidence warranting further
study of PS-341, providing other factors, such as toxicity and
survival, also appeared favorable. If four or fewer responses
in 40 patients were observed in a stratum, further study of
PS-341 would not be warranted in that setting. In either
stratum, the probability of falsely declaring PS-341 as war-
ranting further study was 0.05 () when the true response rate
was 5%; the probability of correctly declaring PS-341, if the
true response rate was 20%, as warranting further study
was 0.92 (power). Upon full accrual to 40 patients per
stratum, the response rate and the rates of individual toxicities
were anticipated to be within 16% (95% confidence inter-
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val). As the study did not proceed to full accrual, the actual
precision for rate estimates was 19% in each stratum.
Molecular Correlative Studies
As part of this trial, we also attempted to identify
possible prognostic markers for PS-341 in SCLC. Specifi-
cally, we tested proteins that were relevant to apoptosis
induction, the ubiquitin pathway of degradation, and to che-
motherapy response such as members of the Bcl2 family
(Bcl2, Bcl-xL, and Bax), NF-B, and p27. We originally
hypothesized that low Bcl2/Bax or Bcl-xL/Bax ratios will
correlate with increased response to PS-341, that reduction of
proteasome activity (due to PS-341) will result in decreased
levels of NF-B in the nuclei of cells, and that increased
levels of p27 in tumor specimens will be found post-treatment
and associated with increased apoptosis and response. Immu-
nohistochemical analysis of p27, Bcl2, Bcl-xL, and Bax were
conducted as previously reported.19
RESULTS
Patient Characteristics and Treatment
Summary
Sixty patients were registered between September of
003 through August of 2004, of which one was deemed
ineligible for not having a prestudy computed tomography or
magnetic resonance imaging of the brain. Of the 59 eligible
patients, 29 had platinum-sensitive disease and 30 were
platinum refractory. Relevant patient characteristics are sum-
marized in Table 1.
The reasons for protocol discontinuation are summa-
rized in Table 2. The majority of patients (71%) were taken
off protocol for disease progression. An additional 18% of
patients went off study due to adverse events or side effects.
Efficacy
Tumor response is summarized in Table 3. Only one
patient with platinum-refractory disease had a confirmed
response (Figure 1). The majority of patients (83%) had
progressive disease and/or symptomatic deterioration. An
additional three patients (5%) were not adequately assessed
for response due to the following reasons: early discontinu-
ation of treatment for toxicity, failure to provide follow-up
measurements in a patient who did eventually progress while
on treatment, early discontinuation of treatment due to de-









0 9 (32) 7 (25)
1 19 (68) 21 (75)





Males 17 (61) 15 (54)
Females 11 (39) 13 (46)
LDH
Above IULN 10 (36) 11 (36)
Normal range 11 (39) 10 (39)
Unreported 7 (25) 7 (25)
Weight loss past 6 mo
5% 21 (75) 22 (79)
5 to 10% 5 (18) 4 (14)
10% 1 (4) 2 (7)
Unreported 1 (4) 0 (0)
Metastatic site(s)
None 1 (4) 0 (0)
One lesion, single
organ
5 (18) 3 (11)
Multiple lesions,
single organ
9 (32) 5 (18)
Multiple organs 12 (43) 20 (71)




1 11 (39) 14 (50)
2 8 (29) 6 (22)
3 4 (14) 4 (14)
4 4 (14) 3 (11)
Unreported 1 (4) 1 (4)
LDH, lactate dehydrogenase; IULN, institutional upper limit of normal.






No. of patients 56 28 28
Reasons
Adverse events or side effects 10 3 7
Refusal unrelated to adverse events 0 0 0
Progression/relapse 40 23 17
Death 3 1 2
Other, not protocol specified 3 1 2






Complete response 0 (0) 0 (0)
Partial response 0 (0) 1 (4)
Stable/no response 0 (0) 2 (7)
Progressive disease 21 (75) 20 (71)
Symptomatic deterioration 4 (14) 3 (11)
Early death 1 (4) 1 (4)
Assessment inadequate 2 (7) 1 (4)
Total 28 (100) 28 (100)
Totals may not add up to 100% due to rounding.
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clining condition. Two patients died due to causes other than
cancer before the first disease assessment. There were two
patients, both of whom were platinum refractory, who had
stable disease. Because of rapid accrual, 30 patients had been
entered in each stratum at the first accrual stage before the
planned interim response assessment. Despite the sole plati-
num-refractory responder, we decided not to reopen the
second accrual stage due to the very high rate of disease
progression, particularly in the first two cycles.
Median progression-free and overall survival times in
the platinum-refractory stratum were 1.1 months (95% con-
fidence interval [CI]: 0.82–1.2) and 3.1 months (95% CI:
1.6–3.5), respectively. Median progression-free and overall
survival times in the platinum-sensitive stratum were 1.2
months (95% CI: 1.15–1.25) and 2.9 months (95% CI: 1.9–
3.5), respectively. The 6-month progression-free survival rate
was 10% in the platinum-refractory stratum and zero in the
platinum-sensitive stratum, whereas the 6-month overall sur-
vival rate was 25% in both strata. The Kaplan-Meier curves
for overall survival can be seen in Figure 2.
Toxicity
Treatment was generally well tolerated. The most com-
mon attributable toxicities exceeding grade 2 were fatigue
(eight events, only one was grade 4) and thrombocytopenia
(nine events, only two were grade 4). There were three
FIGURE 1. Confirmed partial response to PS-341 in a patient with platinum-refractory small cell lung cancer.
FIGURE 2. Kaplan-Meier overall
survival curves.
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on-study deaths, two in the platinum-refractory stratum: two
were due to disease progression and the other was due to
dyspnea/respiratory failure (possibly related to PS-341). A
summary of the most common toxicities in this trial can be
found in Table 4.
Molecular Correlates
Unfortunately, no posttreatment tumor samples were
collected during the trial due to rapid disease progression and
demise of many of the enrolled patients. Therefore, the only
analyses that could be performed were with immunohisto-
chemistry for all the markers on available pretreatment sam-
ples. Two of eight patients showed abnormally low p27
levels. Five patients showed abnormally low BAX levels, and
six patients had abnormally high levels of Bcl-2. The results
for Bcl-xL showed abnormal expression of this antiapoptotic
protein in a high percentage of tumor cells from all eight
specimens (100%). All patients had at least two of these four
markers expressed abnormally, with five patients showing
three proteins abnormally expressed. Even though this was a
small sample size, apoptosis-associated genes were found to
be abnormally expressed frequently in this cohort, consistent
with previous reports. Due to the small number of samples
available and lack of efficacy, no statistical correlates could
be drawn with these markers.
DISCUSSION
PS-341 has been shown to overcome Bcl-2-mediated
resistance to apoptosis.20,21 Bold et al.24 reported that the high
level of Bcl-2 in SCLC is independent of AKT activation,
contrary to the findings in numerous other malignancies.22
Dose-dependent reduction of Bcl-2 protein levels following
24 hours of PS-341 treatment has been described in two
SCLC cell lines (H526 and H69). In this preclinical study, the
decrease in Bcl-2 protein levels paralleled the increase in the
phosphorylated form of IB, whereas no change was ob-
served in levels of the proapoptotic BAX. Finally, dose-
dependent cleavage of PARP was observed in both H526 and
H69 cells after PS-341 treatment, with significant biochemi-
cal manifestations of apoptosis observed at doses as low as 10
nmol/l. The induction of apoptosis was confirmed using
FACS analysis in which increases in the sub-G1 or apoptotic
fraction was observed at increasing PS-341 doses in the H526
and H69 cells.
However, in the clinical trial reported herein, single-
agent PS-341 induced a response in only one patient who had
platinum-refractory disease. Nevertheless, the sole platinum-
refractory responder serves as proof of principle for the
concept of proteasome inhibition in SCLC. It is also worth
emphasizing that this trial was not a second-line trial. In fact,
patients enrolled in this trial were allowed to have had any
number of previous chemotherapy regimens. More than half
the patients enrolled had received two or more previous
chemotherapy regimens. Thus, the patient population in
which we tested PS-341 likely has established resistance
mechanisms and/or new molecular aberrations that resulted in
a more resistant phenotype.
Hypothetically, when administered in combination,
chemotherapy will serve to initiate the apoptotic process,
whereas PS-341 functions to lower the barriers to apoptosis.
For example, there is evidence that combining PS-341 with a
camptothecin could have additive cytotoxic activity in solid
tumors. A study using the LOVO, KM12L4, WiDR, and
CCD841 colon cancer cell lines examined the inhibitory
effect of treatment with PS-341 and SN-38, the active me-
tabolite of the camptothecin irinotecan, compared with treat-
ment with either drug alone. Growth inhibition was 64% to
75% for the drug combination versus 20% to 30% for PS-341
alone and 24% to 47% for SN-38 alone (p  0.002).23 In a
LOVO xenograft model, a 94% decrease in tumor size was
seen for the combination of PS-341 and irinotecan, compared
with 26% and 48%, respective, decreases for PS-341 and
irinotecan when given singly (p  0.02).
These observations form the rationale for future study
of PS-341 in combination with a camptothecin (such as
topotecan). Camptothecins can induce down-regulation of
topoisomerase I via the ubiquitin/26S proteasome pathway.
This down-regulation has been associated with camptothecin
resistance. Therefore, 26S proteasome inhibition by PS-341
can potentially enhance camptothecin sensitivity by prevent-
ing topoisomerase-I down-regulation and increasing topoi-
somerase-I levels.24 Furthermore, topoisomerase inhibitors
can induce NF-B, which likely acts as a survival mechanism
in response to such therapy.25,26 Therefore, repression of
NF-B through PS-341 may theoretically enhance activity of
this class of agents. To test the clinical feasibility of this
concept, a phase I trial of topotecan plus bortezomib has
recently been initiated at the UC Davis Cancer Center. Cur-
rent plans are to take this combination into the phase II setting
after a maximum tolerated dose is identified.
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